Menu

Markets

Research

News

Learn

AI Chat
Get the app WatchlistsPortfoliosAlerts
Pricing Sign in

Roivant Sciences Ltd. ROIV

Full chart Compare
Set alert

Price alert · ROIV

All alert types
41.19 USD +0.52 (+1.28%)

At closeNov 11, 2026, 5:57 AM EST

41.46 +0.27 +0.65%

Pre-market · Nov 11, 5:57 AM ET

39.88 Day range 41.37
19.96 52-week range 42.50
YTD
+89.82%
1 year
+97.08%
Market cap
29.84B
Revenue (ttm)
41.08M
EPS (ttm)
-0.65
Shares out
724.56M
Forward P/E
-29.59
YTD return
+89.82%
1-year return
+97.08%
Volume
10.59M
Avg volume
7.99M
Open
40.60
Previous close
40.67
Day's range
39.88 – 41.37
52-week range
19.96 – 42.50
Beta
1.20
Analysts
Strong Buy
Price target
49.91 (+21.2%)
Earnings date
Feb 5, 2027
1D5D1M3M6MYTD1Y2Y5YMAXALL
Customize chart

5D +4.79 (+13.16%)

363840WedThuFriMonTue41.19

Key statistics

Financials
Enterprise value
25.94B
PEG ratio
0.00
Price / sales
726.47
Price / book
7.41
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
2135.60%
Free cash flow
-358.86M
Total cash
4.21B
Total debt
106.57M
Return on equity
-8.54%
Short % of float
7.55%
50-day average
36.81
200-day average
31.94

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 49.91 +21.2% upside
Target (low)
41.00
Target (mean)
49.91
Target (high)
62.00
Ratings (0m) 13 11 buy · 2 hold · 0 sell
  • Strong buy2
  • Buy9
  • Hold2
  • Sell0
  • Strong sell0

Next earnings

Feb 5, 2027

Expected Feb 5, 2027. Consensus EPS estimate -0.40348.

Earnings history

Financials — quick view

All financials
ROIV Revenue — quarterly 35.12M
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026
ROIV Net income — quarterly -191.62M
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026
ROIV EPS — quarterly -0.27
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026

Earnings

ROIV recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 5, 2027Dec 30, 2026-0.36———
Nov 9, 2026Sep 30, 2026-0.36664-0.27+0.10+26.36%
Aug 6, 2026Jun 30, 2026-0.29962-0.33-0.03-10.14%
May 20, 2026Mar 31, 2026-0.28931-0.2792+0.01+3.49%
Feb 6, 2026Dec 31, 2025-0.29954-0.24+0.06+19.88%
Nov 10, 2025Sep 30, 2025-0.3198-0.20193+0.12+36.86%

Upgrades / downgrades

ROIV analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026HC Wainwright & Co.mainBuyBuy
Oct 28, 2026CitigroupmainBuyBuy
Oct 12, 2026Wolfe ResearchdownOutperformPeer Perform
Sep 17, 2026Stifelinit—Buy
Sep 9, 2026TD CowenmainBuyBuy
Sep 9, 2026GuggenheimmainBuyBuy

About Roivant Sciences Ltd.

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom
Website
roivant.com

News

All news

Your note

Sign in to keep a note on ROIV — it syncs with the Stock Master app.

Insider holders

ROIV insider holders
InsiderRelationLatest transactionDateShares held
GLINE MATTHEWChief Executive OfficerSaleApr 15, 202616,736,100
GOLD DANIEL ALLENDirectorSaleJun 29, 20260
KUMAR RAKHIOfficerSaleFeb 12, 2025163,264
MANCHESTER KEITH SDirectorStock Award(Grant)Sep 15, 20261,753,460
OREN ILANDirectorStock Award(Grant)Oct 22, 2026124,490
PULIK RICHARDChief Financial OfficerStock Award(Grant)Apr 19, 2026297,511

Institution ownership

ROIV institution ownership
Holder% heldSharesValueReported
FMR, LLC11.22%81,020,3903.34BJun 29, 2026
Blackrock Inc.6.68%48,236,0911.99BJun 29, 2026
Morgan Stanley5.90%42,592,9051.75BJun 29, 2026
QVT Financial LP3.28%23,723,074977.15MJun 29, 2026
Vanguard Capital Management LLC3.06%22,123,198911.25MJun 29, 2026
Vanguard Portfolio Management LLC3.00%21,641,339891.41MJun 29, 2026

Fund ownership

ROIV fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund3.23%23,359,928962.20MSep 29, 2026
iShares Trust-iShares Core S&P Mid-Cap ETF2.67%19,297,013794.84MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.21%15,987,737658.53MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund1.60%11,546,280475.59MJun 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco S&P MidCap Momentum ETF0.96%6,900,746284.24MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.93%6,740,514277.64MSep 29, 2026